PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17401602-8	2007	Nicotine-induced LIF-to-MYF transdifferentiation was almost completely reversed by treatment with RGZ, PTHrP, or DBcAMP, as determined by protein and functional assays.	Nicotine	0-8	LIF interleukin 6 family cytokine	Homo sapiens	17-20	
17401602-2	2007	Modulation of PTHrP-driven signaling can almost completely prevent nicotine-induced LIF-to-MYF transdifferentiation.	Nicotine	67-75	LIF interleukin 6 family cytokine	Homo sapiens	84-87	
17401602-4	2007	Our objective was to determine if nicotine-induced LIF-to-MYF transdifferentiation could be reversed by specifically targeting the PTHrP-mediated alveolar epithelial-mesenchymal paracrine signaling.	Nicotine	34-42	LIF interleukin 6 family cytokine	Homo sapiens	51-54	
17401602-9	2007	Using a specific molecular approach and targeting specific molecular intermediates in the PTHrP signaling pathway, to our knowledge, this for the first time, demonstrates the reversibility of nicotine-induced LIF-to-MYF transdifferentiation, suggesting not only the possibility of prevention but also the potential for reversal of nicotine-induced lung injury.	Nicotine	192-200	LIF interleukin 6 family cytokine	Homo sapiens	209-212	
17401602-9	2007	Using a specific molecular approach and targeting specific molecular intermediates in the PTHrP signaling pathway, to our knowledge, this for the first time, demonstrates the reversibility of nicotine-induced LIF-to-MYF transdifferentiation, suggesting not only the possibility of prevention but also the potential for reversal of nicotine-induced lung injury.	Nicotine	331-339	LIF interleukin 6 family cytokine	Homo sapiens	209-212